WAYNE, PENNSYLVANIA – March 1, 2019: Falcon Capital Partners, LLC (“Falcon”), a leading middle-market investment bank, is pleased to announce the merger of daVIZta Inc. (“daVIZta”), with Integrichain Incorporated (“IntegriChain”), a portfolio investment of Accel-KKR (“AKKR”).

Founded in 2010 and headquartered in Somerset, NJ, daVIZta is a provider of enterprise revenue analytics solutions and services to the life sciences industry. This trillion dollar market continues to grow as the demand for revenue cycle management solutions is driven by pharmaceutical companies outsourcing more operations that have historically been conducted in-house. daVIZta’s solutions include the d-Rive suite of software applications as well as managed services and advisory services led by its team of subject matter experts with deep domain knowledge, to help customers address their critical needs throughout the entire life cycle of a drug.

Headquartered in Philadelphia, PA, IntegriChain is a life sciences commercial data and analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation and adherence. Since 2016, IntegriChain has been backed by AKKR, a leading Silicon Valley technology private equity firm. This acquisition strengthens IntegriChain’s comprehensive life sciences commercial data and analytics platform for payer, patient, and distribution, and expands its team of world-class data science and life science experts to 220.

daVIZta’s expertise in gross-to-net (G2N) automation and government pricing solutions represent key challenges for commercial-stage life sciences companies to ensure access to new and existing therapies and will become a key area of focus for the combined entity. Per IntegriChain Co-Founder and CEO Kevin Leininger, “Gross-to-net is a key industry obstacle for life sciences, with continuous headlines and regulatory uncertainty placing immense pressure on financial modeling and forecasting. The addition of daVIZta’s payer technology and expertise uniquely positions us to partner with industry to solve the G2N and pricing challenges of today and tomorrow.” Shekhar Yerramilli, Chairman and CEO of daVIZta, adds, “We are excited to join forces with IntegriChain to overcome the access barriers that manufacturers face in today’s increasingly complex and evolving regulatory environment. IntegriChain offers our customers an extensive access solution platform, delivering unrivaled reporting, analytics, and on-demand data accessibility for all of the data inputs that are central to the G2N challenges we are passionate about solving.”

Falcon served as exclusive sell-side advisor to daVIZta. Co-Founders Shekhar Yerramilli and Krishnan Padmanabhan wrote, “As we prepared for this process, we sought an M&A advisor who would listen to our goals and objectives and would consider the best interests of our team members and clients in the process. The Falcon team led by Managing Director Ted Stack proved themselves as knowledgeable about the pharma technology market, familiar with the challenges of a global delivery provider, and skilled in guiding us through an efficient process with a successful outcome.”

The terms of the transaction were not disclosed. The complete press release can be found here.

This transaction represents Falcon’s continued work in the life sciences services and technology markets within the firm’s broader healthcare focus. The Falcon deal team was led by Managing Director Ted Stack, Vice President Don Wanner, and Senior Associate Conrad Olenik. For more information please contact Ted at tstack@falconllc.com, 610-989-8901, Don at dwanner@falconllc.com 610-989-8907, or Conrad at colenik@falconllc.com, 610-989-8905.